GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Edesa Biotech Inc (NAS:EDSA) » Definitions » ROC (Joel Greenblatt) %

Edesa Biotech (Edesa Biotech) ROC (Joel Greenblatt) % : -7,593.44% (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Edesa Biotech ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Edesa Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -7,593.44%.

The historical rank and industry rank for Edesa Biotech's ROC (Joel Greenblatt) % or its related term are showing as below:

EDSA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -13193.89   Med: -909.82   Max: -440.09
Current: -6645.35

During the past 13 years, Edesa Biotech's highest ROC (Joel Greenblatt) % was -440.09%. The lowest was -13193.89%. And the median was -909.82%.

EDSA's ROC (Joel Greenblatt) % is ranked worse than
89.32% of 1470 companies
in the Biotechnology industry
Industry Median: -339.53 vs EDSA: -6645.35

Edesa Biotech's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -66.00% per year.


Edesa Biotech ROC (Joel Greenblatt) % Historical Data

The historical data trend for Edesa Biotech's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edesa Biotech ROC (Joel Greenblatt) % Chart

Edesa Biotech Annual Data
Trend Aug14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -440.09 -3,200.50 -844.57 -1,166.90 -13,193.89

Edesa Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10,065.61 -6,494.28 -6,326.44 -6,446.85 -7,593.44

Competitive Comparison of Edesa Biotech's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Edesa Biotech's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Edesa Biotech's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Edesa Biotech's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Edesa Biotech's ROC (Joel Greenblatt) % falls into.



Edesa Biotech ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.627 + 0 + 0.449) - (1.747 + 0 + 0)
=-0.671

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.744 + 0 + 0.404) - (1.909 + 0 + 0)
=-0.761

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Edesa Biotech for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-6.948/( ( (0.1 + max(-0.671, 0)) + (0.083 + max(-0.761, 0)) )/ 2 )
=-6.948/( ( 0.1 + 0.083 )/ 2 )
=-6.948/0.0915
=-7,593.44 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Edesa Biotech  (NAS:EDSA) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Edesa Biotech ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Edesa Biotech's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Edesa Biotech (Edesa Biotech) Business Description

Traded in Other Exchanges
N/A
Address
100 Spy Court, Markham, ON, CAN, L3R 5H6
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.
Executives
Stephen Lemieux officer: Chief Financial Officer 100 SPY COURT, C/O EDESA BIOTECH, INC., MARKHAM A6 L3R 5H6
Joan Chypyha director 100 SPY COURT, MARKHAM A6 L3R 5H6
Patrick Marshall director 100 SPY COURT, MARKHAM A6 L3R 5H6
Van Der Velden Peter director, 10 percent owner C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Michael J Brooks officer: President C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Pardeep Nijhawan director, 10 percent owner, officer: Chief Executive Officer C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Jennifer M Chao director 7 PURITAN WOODS ROAD, RYE NY 10580
Frank R. Oakes director, officer: President, CEO, & Director C/O STELLAR BIOTECHNOLOGIES, INC., 332 EAST SCOTT STREET, PORT HUENEME CA 93041
Sean Arthur Macdonald director C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Lorin K Johnson director 3600 W BAYSHORE ROAD SUITE 205, PALO ALTO CA 94303
Pardeep Nijhawan Medicine Professional Corp 10 percent owner C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Paul William Pay director C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Carlo Sistilli director C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Lumira Capital Investment Management Inc. 10 percent owner 141 ADELAIDE STREET WEST, SUITE 770, TORONTO A6 M5H 3L5
Daniel E. Morse director C/O STELLAR BIOTECHNOLOGIES, INC., 332 EAST SCOTT STREET, PORT HUENEME CA 93041

Edesa Biotech (Edesa Biotech) Headlines